SUBSCRIBE
SUBSCRIBE
News   Drug Development

Icagen, Inc. Provides Update Regarding Clinical Development Plans for ICA-105665

April 27, 2010 | 
1 min read

RESEARCH TRIANGLE PARK, N.C., April 27, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today provided an update on clinical development plans for ICA-105665, the Company’s novel drug candidate for the treatment of epilepsy and pain.

Clinical research Phase II
MORE ON THIS TOPIC
A white blood cell charging an ADC/
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong